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Anorexia, defined as the loss of the desire to eat, is relatively
common in hemodialysis (HD) patients, occurring in
one-third of cases. The pathogenesis is essentially unknown.
It has been proposed that uremic toxins as middle molecules,
inflammation, altered amino-acid pattern, leptin, ghrelin, and
neuropeptide Y are involved. Anorexia reduces oral energy
and protein intakes, thus contributing to the development of
malnutrition and cachexia. Unquestionably, it contributes to
poor quality of life. The clinical relevance of anorexia as an
independent prognostic factor in HD patients is a matter of
debated issue. The treatment of this debilitating condition is
based on a therapeutic strategy which may include daily
dialysis sessions and nutritional counseling. Normalization of
plasma branched-chain amino acids through branched-chain
amino acids supplementation may decrease anorexia and
improve energy and protein intake. The role of megestrol
acetate as appetite stimulant needs to be validated through
adequate randomized trials. Subcutaneous ghrelin
administration and melanocortin-receptor antagonists
appear promising therapeutic interventions.
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Malnutrition is highly prevalent in hemodialysis (HD)
patients and significantly affects morbidity and mortality.1
Inadequate dietary intake, secondary to anorexia, underlying
illness, taste abnormalities, loss of dentures, gastropathy,
enteropathy, medications, psychosocial conditions, aging and
HD-related factors, are some of the most frequent and
important causes of malnutrition in HD patients.1–2
Anorexia, defined as the loss of the desire to eat, is
relatively common in HD patients, contributes largely to
malnutrition, affects quality of life, and is associated with an
increased risk of morbidity and mortality.1–2
The present review will discuss the clinical features,
possible pathogenic mechanisms and treatment of this
debilitating condition.
PREVALENCE
Anorexia is present in about one-third of HD patients.
Kalantar-Zadeh et al.3 have shown that diminished appetite
was reported in 124 out of 331 (38%) HD patients and that,
of these, 7% had poor appetite and 31% had fair appetite,
and none complaining to suffer from very poor appetite.
Similarly, in the Hemodialysis (HEMO) Study, one-third of
1846 HD patients included in the trial reported a diminished
appetite: fair in 23.8% and poor or very poor in 8.8%.4
Similar to these data, Bossola et al.2 have recently shown, that
anorexia was present in 37.8% of cases. Interestingly,
Burrowes et al.5 reported that an higher percentage of
patients had poor or very poor appetite on dialysis treatment
days (12.7%), than on non-dialysis treatment days (5.4%). As
consequence, the mean weight-adjusted dietary energy and
protein intake diminished significantly from non-dialysis
treatment days to dialysis treatment days from 77.5 kcal/day
to 4.79 g/day. An energy deficit of 77.5 kcal per dialysis
treatment days amounts to an estimated annual deficit of
12 500 kcal and this translates into significant lower dietary
energy and protein intake.
DIAGNOSTIC TOOLS
The presence of anorexia and its degree can be evaluated
through the first three questions of the Appetite and Diet
Assessment Tool.3–4 The responses to the first question,
During the last week, how would you rate your appetite?,
adhered to a five-point Likert scale: (1) very good, (2) good,
(3) fair, (4) poor, and (5) very poor. The second and third
questions ask whether there had been a change in appetite in
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the last week and, if so, whether had appetite increased,
remained the same, or decreased.
Food record, diet recall or diet history are also useful
tools to evaluate the presence of disturbed appetite.1–2 The
HEMO study showed that higher appetite scores were
associated significantly with increasing dietary energy and
protein intakes measured by 2-day diet dairy-assisted recall
and dietary intakes declined steadily with poorer appetite
scores.5
CLINICAL EFFECTS
Anorexia reduces oral energy and protein intakes, thus
contributing to the development of malnutrition and
cachexia. 1–3 Anorexic patients, when compared with non-
anorexic ones, had lower dietary energy, and protein intakes,
lower levels of serum albumin and total lymphocytes, and a
higher weight loss during the last 6 months.2 In the study of
Kalanthar–Zadeh et al.3 the protein intake was progressively
and significantly lower as appetite categories (poor, fair,
good, very good) worsened; a similar trend was also found
for blood haemoglobin, serum albumin, and prealbumin. In
the HEMO Study, lower values for energy and protein
intakes, serum albumin, creatinine, post-dialysis weight, and
upper arm and calf circumference were observed with poorer
appetite ratings.4 Interestingly, some authors have observed a
greater reduction of daily energy intake than daily protein
intake in stable chronic HD patients.6
The clinical relevance of anorexia as an independent
prognostic factor in HD is an argument of debate. Some
authors have demonstrated that the mortality hazard ratio
nearly doubled across each of the four worsening appetite
categories (very good, good, fair, poor) and that, after the
appetite categories were dichotomized, anorexia was asso-
ciated with an increase (B4.5–5 times) in mortality risk.3 On
the other hand, the HEMO study reported that, after
adjustment for demographic factors and randomized treat-
ment assignments, there was a significant association between
poorer self-reported appetite and death but the association
became non-significant with further adjustment for comor-
bidity.4 However, poorer appetite was unequivocally asso-
ciated with increased hospitalization rates.6 Unquestionably,
anorexia contributes to poor quality of life. In the HEMO
Study, the health-related quality of life measured by the
Medical Outcomes Study Short Form-36 (MOS-SF-36) was
lower among patients with poor appetite even after
controlling for comorbidities and dose of HD.7 Poor appetite
was also associated with both lower Physical Component
Scale and Mental Component Scale of the MOS-SF-36.
PATHOGENESIS
The pathogenesis of anorexia in HD patients is essentially
unknown. It has been proposed that uremic toxins as middle
molecules, inflammation, altered amino-acid pattern, hor-
mones (e.g. leptin and ghrelin), and neuropeptides (e.g.
neuropeptide Y (NPY)) are involved.1,8 A perturbed taste
sensitivity may also have a role in reducing appetite and
dietary intake in HD patients. However, the link between
taste sensitivity and food consumption is largely unstudied in
such patients. However, many are the mediators that might
be implicated in uremic anorexia and they need to be
evaluated in further adequate studies (Table 1).
Middle size molecules
In 1996, Anderstam et al.9 demonstrated that intraperitoneal
injection of uremic plasma ultrafiltrate into normal rats
inhibits ingestive behavior. The effect was not specific for one
type of nutrient, but was seen to affect the intakes of
carbohydrate, protein, and a mixed nutritional solution to
about the same extent. The absence of an effect on ingestive
behavior of the non-uremic plasma ultrafiltrate supported
the conclusion that the inhibition of the uremic ultrafiltrate is
a feature of uremic intoxication. The observation that the
ingestion of sucrose and the mixed nutritional solution were
reduced after the injection of ultrafiltrate of normal urine
suggests that one or more toxic factors that are normally
eliminated from the body by urinary excretion accumulate in
the body fluids of patients. Uremic plasma and urine
fractions with the strongest dose-dependent anorexic activity
had a molecular weight of 1–5 kd. In a subsequent study,
Mamoun et al.10 demonstrated that a intracerebroventricular
injection of 5 or 10 ml of urine middle molecule fraction
inhibited carbohydrate intake by 13.4 and 41.6%, respectively
and that an injection of 5 or 10 ml of uremic plasma
ultrafiltrate middle molecule fraction inhibited carbohydrate
intake by 22.6% and 49.5%, respectively. However, the
physiological effect of middle molecules on the brain is
unknown, as yet little is known about their exact molecular
weight and availability to the brain. Interestingly, taking into
account that doses of middle molecules fractions that
effectively inhibited ingestive behavior had no effect on
sexual behavior, the inhibitory effects of middle molecules
seems to be specific for ingestive behavior.
Table 1 | Mediators possibly implicated in HD-related
anorexia
Orexigenic
Ghrelin
Neuropeptide Y
Agouti-related peptide
Anorexigenic
Leptin
Cholecystokinin
Insulin
Melanocortin
a-melanocyte-stimulating hormone
Serotonin
Tryptophan
Polypeptide YY
Corticotropin-releasing hormone
TNF-a
Interleukin-1b
HD, hemodialysis; TNF-a, tumor necrosis factor-alpha.
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Inflammation
A strong and consistent association between anorexia and
high levels of inflammatory markers has been shown by
Kalantar-Zadeh et al.3 in a cohort of 331 HD patients. Serum
concentrations of C-reactive protein, interleukin-6, and
tumor necrosis factor-a (TNF-a) increased significantly with
diminishing appetite. The values for all three inflammatory
markers in patients with poor, fair, good, or very good
appetite were approximately twice the upper limit for the
general population. Aguilera et al.11 found high TNF-a
plasma levels in 97.6% of 42 peritoneal dialysis patients and
showed that anorectic patients had higher TNF-a levels than
non-anorectic patients. Non-anorectic patients suffering
other gastrointestinal symptoms also had higher levels of
TNF-a than asymptomatic patients. Indeed, it is well known
that cytokines are able to inhibit appetite both in healthy
conditions and in various diseases (cancer, sepsis, cardiac
cachexia, chronic obstructive pulmonary disease).12 It has
been extensively demonstrated that cytokines induce ano-
rexia by acting on meal size, meal duration, and meal
frequency differentially; that specific cytokines may be
transported from the periphery to the brain and cytokines
generate mediators that can act on peripheral and/or brain
target sites; that cytokines act directly on hypothalamic
neurons proposed to participate in feeding.12
Altered amino-acid pattern
The amino-acid profile in end-stage renal disease (ESRD)
with or without dialysis exhibits abnormal patterns, such as
reduced essential/non-essential amino-acids ratio and lower
branched amino acids (BCAA) levels.13 It is well known that
the behavioral outcome of deficiencies of essential amino
acids and BCAA is an anorectic response.14 Reports of
anorexia with essential and branched chain aminoacids
deficiency in animal models date from the early 1900 s.14
Indeed, anorectic HD patients have significantly lower BCAA
levels than non-anorectic patients.15 Recently, it has been
proposed that the low essential and branched chain amino-
acids plasma and cerebrospinal fluid concentrations permits
a high level of tryptophan transport across the blood–brain
barrier, causing an increase in the synthesis of serotonin
responsible for appetite inhibition.16 This hypotheses, named
‘peak-concentration’, is still unproved in HD patients. Indeed,
plasma tryptophan levels in hemodialysed patients have been
shown to be lower than healthy individuals.17 However, it is
well known that hyperammonemia increases the uptake of
tryptophan into the brain by activation of the L-system
carrier.18
Leptin, ghrelin, and NPY
Under normal conditions, energy intake is controlled by the
hypothalamus where peripheral signals convey information
on energy and adiposity status.19 In the hypothalamus, the
arcuate nucleus contains specific neuronal populations that
transduces these inputs into neuronal responses and, via
second-order neuronal signaling pathways, into behavioral
responses.19 Some signals coming from the periphery
(adipose tissue and gastrointestinal tract), such as leptin
and ghrelin, are perturbed in HD patients.1,20 In fact, both
plasma levels of leptin and ghrelin are significantly higher in
HD patients than in controls.1,20 Leptin, a hormone secreted
from adipose tissue as a product of the ob gene expressed
predominantly by adipocytes, influences energy homeostasis,
immune, and neuroendocrine function. Leptin decreases
appetite, in part, by inhibiting neurons that produce the NPY
and the agouti-related peptide, that are orexigenic peptides,
whereas it stimulates neurons in the arcuate-nucleus region
of the hypothalamus to produce melanocortins, that are
anorexigenic.19 On the basis of the observation that ESRD
patients with or without dialysis have inappropriately high
serum leptin levels, it has been speculated that hyperleptine-
mia in ESRD patients may be one of the factors mediating
anorexia and wasting.19 Moreover, through an elegant
experimental study, Cheung et al.21 have shown that leptin
receptor-deficient (db/db) mice, undergoing subtotal ne-
phrectomy and consequently showing elevated circulating
leptin levels, resisted the cachexic effects of uremia on weight
gain, body composition, and metabolic rate. According to the
authors, these results further argue towards the hypotheses
that elevated circulating levels of cytokines such as leptin may
be an important cause of uremia-associated cachexia via
signaling through the central melanocortin system. However,
although some clinical studies have demonstrated that leptin
contributes to malnutrition, others have failed to demon-
strate any relationships between serum leptin and different
nutritional markers and intakes.20 Moreover, Bossola et al.22
confirmed that HD patients have higher levels of serum
leptin than healthy subjects and demonstrated that serum
leptin levels and the serum leptin/body mass index ratio
were not different in anorexic and in non-anorexic HD
patients. No statistically significant differences in serum
leptin levels and leptin/body mass index ratio were observed
between patients with dietary energy intakes of o30 or
X30 kcal/kg/day and between those with a protein intake of
o1.2 or X1.2 g/kg/day. It is possible that a state of
relative leptin resistance may occur in ESRD patients receiv-
ing HD like in obese patients who do not respond to these
increased leptin levels with reduced food intake. This issue
has been recently reviewed by Munzberg and Myers.23
Ghrelin, an orexigenic peptide released primarily from the
oxyntic cells of the stomach, regulates feeding, and body
weight regulation through stimulation of hypothalamic
appetite centers and coordination of energy balance.19 A
common observation is that plasma ghrelin levels are
markedly increased in HD patients with respect to controls.24
Chang et al. have determined the profile of plasma ghrelin
levels over 24 h in non-diabetic HD patients showing a
unique diurnal change without an obvious plasma ghrelin
rise before each meal time and not a rapid fall after eating.25
They also found that the average level of plasma ghrelin in
HD patients was one-fifth higher than in the healthy control
group at most sampling times during the day, except between
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1000 and 1400 According to the authors of the study, these
observations suggest that there is a resistance to ghrelin
action in ESRD patients, either peripheral or central, or both.
The detection of high plasma ghrelin levels in HD patients is
in contrast with the strong tendency of HD patients to be
anorexic. Interestingly, no association was found between
plasma ghrelin levels and estimated protein intake in HD
patients24 whereas Aguilera et al.26 have recently demon-
strated that plasma ghrelin levels are elevated in peritoneal
dialysis patients and that the anorexic ones showed relatively
lower values of ghrelin than did obese patients or patients
with normal appetite. Overall, it seems that the available data
do not allow definitive and clear considerations on the
significance of high plasma ghrelin level as well as on its role
in the perturbation of feeding behavior that occurs in many
HD patients.
NPY is the most potent orexigen factor known.19
Unfortunately, there are no studies in HD patients who have
evaluated the plasma NPY levels and none have correlated
them with the presence of anorexia and with nutritional
parameters. Lower than normal NPY plasma values have
been shown in 22% of peritoneal dialysis patients, normal
values in 66%, and high values in 12%.11 NPY values were
lower in anorexic (43.2727.5 pg/ml) than in non-anorexic
patients (64.9725.5; Po0.05). Patients with gastrointestinal
symptoms also showed lower values than those without.
Interestingly, the NPY plasma levels had a significant inverse
correlation with plasma TNF-a levels.
TREATMENT
The treatment of anorexia in HD patients is based on a
therapeutic strategy which may include frequent dialysis
sessions, nutritional counseling, and nutritional and pharmaco-
logical approaches (Table 2).
Increase in number of dialysis sessions
The increase in the number of dialysis sessions through daily
HD has been shown to improve appetite and food intake.27
This is probably owing to a general feeling of well-being,
increased physical activity, fewer dietetic restrictions, de-
creased dose of medications such as phosphate binders and
antihypertensive drugs. It has also been suggested that daily
HD increases the clearance of potential anorexic factors.27
Moreover, it seems that daily HD significantly increases
serum albumin and cholesterol levels, and dry body weight.27
With conventional thrice weekly regimens, the dialysis dose
increase or the use of high dialysis flux does not seem to
improve appetite and dietary intake. In the HEMO study, self-
reported appetite rating did not differ significantly in either
the dialysis dose or membrane flux treatment groups. This
translated in similar dietary energy and protein intakes.4–5
Although no specific data exist about the effect of
hemodiafiltration, acetate-free biofiltration, and biofeedback
technique on appetite and dietary intake, it is possible that,
based on their better depuration and control of intradialytic
symptoms, they could influence HD-related anorexia. How-
ever, it remains to be defined through adequate studies if
these techniques might have a significant role in improving
appetite, dietary intake, and ultimately nutritional status.
Nutritional counseling
A comprehensive nutritional, diet and appetite assessment to
identify if nutritional status is too low is mandatory and so is
the definition of problems related to self-feeding, access to
food, gastrointestinal distress, and eventually, it is necessary
to identify active psychic, social, medical, dialytic, or
medicinal-related issues that could affect food intake.1–2
Dietary counseling to correct reduced or unhealthy nutrient
intake, performed by a nutritionist has been shown to be
useful. Akpele and Bailey28 have recently demonstrated in
stable HD patients with inadequate dietary intake that the
rate of change in serum albumin level was significantly
greater among patients randomized to receive intensive
nutritional counseling than among those who received oral
supplements. On average, the serum albumin level increased
0.06 g/dl per month for patients randomized to the dietary
Table 2 | Actual and potential therapeutic interventions for anorexia of dialysis patients: results of clinical studies
Author
No. of
patients
Type of
intervention/
treatment Duration Effects
Akpele and Bailey28 40 Dietary counseling 14 months Serum albumin increase
Burrowes et al.29 1 Megestrol acetate 320 mg/day for 24 weeks Improvement of reported appetite, increase of energy
and protein intakes, fat mass increase, decrease of
fat-free mass
Boccanfuso et al.30 17 Megestrol acetate 400 mg BID for 6 months Improvement of appetite and increase of dry weight
Rammohan et al.31 10 Megestrol acetate 400 mg/day for 16 weeks Improvement of appetite, energy and protein intake,
quality of life
Williams et al.32 18 Megestrol acetate 160 mg/day for 3 months No significant increase in serum albumin and lean body
mass
Hiroshige et al.15 28 Oral
supplementataion of
branched chain
amino acids
12 g/day for 12 months Anorexia and dietary intake improvement. Increase in
serum albumin levels and anthropometric indices
Wynne et al.19 9 (peritoneal
dialysis
patients)
Subcutaneous
ghrelin
One single
administration
Increase of energy intake over the following 24 h
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counseling and decreased 0.04 g/dl per month for those
randomized to the dietary supplement group.
Appetite stimulants
Megestrol acetate (MA) is a synthetic, orally active derivate of
the naturally occurring hormone progesterone. MA may
induce appetite via stimulation of NPY in the hypothalamus,
modulation of calcium channels in the ventromedial
hypothalamus, a well known satiety center, and inhibition
of the activity of proinflammatory cytokine such as
interleukin-1, interleukin-6, and TNF-a1 MA has been found
to improve appetite, caloric intake, and nutritional status in
cancer patients.1 Few studies has been conducted in HD
patients.29–32 After administration of a moderate dose of MA
(X320 mg/day) to a chronic HD patient, a fat mass increase
(by 163%) and a fat-free mass decrease (by 10.6%) as
consequence of improvement of reported appetite and
increases of energy and protein intakes has been observed.29
MA administered long term in 17 HD patients and in three of
these for 5–6 months, improved appetite and an increase in
dry weight was reported.30 Rammohan et al.31 demonstrated,
in 10 hypoalbuminemic dialysis patients, that the daily
administration of 400 mg of MA solution for 16 weeks
improved appetite, protein and energy intake, and quality of
life. Williams et al.32 conducted a double-blind, crossover
study in 24 HD patients with poor appetite and serum
albumin less than 4 g/dl who received MA (160 mg/day) or
placebo for 3 months and then switched to the other therapy.
Four patients withdrew because of diarrhea and two died
owing to comorbid conditions. In the 18 patients completing
the study, no significant increase in albumin or lean body
mass was observed. It is well known that MA can induce
many side effects such as headaches, dizziness, confusion,
diarrhea, hyperglicemia, thromboembolic phenomena,
breakthrough uterine bleeding, peripheral edema, hyperten-
sion, adrenal suppression, and adrenal insufficiency.1 On the
basis of these considerations, it seems that the use of MA in
the clinical practice cannot be recommended. Large,
randomized, controlled trials are warranted to really define
the exact role of MA in preventing and treating anorexia in
HD patients.
Oral BCAA supplementation
Hiroshige et al.15 randomly assigned 28 malnourished
patients with anorexia and low-plasma albumin levels to
the administration of BCAA supplementation (12 g/day) or
placebo. In patients receiving BCAA supplementation, ano-
rexia, and poor oral and protein, and caloric intakes improved
within a month concomitant with the improvement in
plasma BCAA levels over the values in well-nourished
patients. After 6 months of BCAA supplementation, anthro-
pometric indices showed a statistically significant enhance-
ment and serum albumin levels increased from 3.3 g/dl to
3.9 g/dl. After exchanging BCAA for placebo, spontaneous
oral food intake decreased, although the favorable nutritional
status persisted for the next 6 months.
These data, although preliminary, suggest that normal-
ization of plasma BCAA levels may decrease anorexia and
improve energy and protein intake in HD patients. However,
they need to be validated in larger trials.
Perspectives
Although plasma ghrelin levels are increased in dialysis
patients, a single subcutaneous administration of ghrelin has
been shown to determine a twofold increase in short-term
energy intake for each individual in a cohort of mild-
to-moderate malnourished peritoneal dialysis patients (the
mean energy intake increased from 440780 to 690760 kcal),
and this increase was followed by a trend toward increased
energy intake over the following 24 h.33 Interestingly, there
was no subsequent compensatory reduction in energy intake
over the following 72 h. Ghrelin administration resulted in a
significant decrease in mean arterial blood pressure, without,
however, symptomatic hypotension or reflex tachycardia. It
remains to be defined if long-term ghrelin administration
may have the potential to improve nutritional status and
patients’ outcome. Further randomized, controlled studies
are warranted to define if subcutaneous ghrelin may have a
role in the treatment of anorexia of HD patients. The central
melanocortin system has been recognized as an important
regulator of energy balance for several years.34 Activation of
hypothalamic MC4 receptor by the endogenous agonist
a-melanocyte stimulating hormone decreases food intake and
leads to an increase in energy expenditure, whereas blockade
of the MC4 receptor by the endogenous MC4-R inverse
agonist, the agouti-related protein, increases food intake,
decreases energy expenditure and leads to weight gain.34 It
has been demonstrated, in experimental studies, that MC4-R
blockade through the central administration of agouti-related
peptide or the MC3/4-R antagonist SHU-9119 protect
animals against uremic anorexia and cachexia.21 MC4
antagonists appear an attractive therapeutic approach for
the anorexia-cachexia syndrome and may have a role also in
ESRD patients receiving maintenance HD.
CONCLUSION
Anorexia, relatively common in HD patients, has detrimental
effects on the nutritional status, the quality of life and
survival. The therapeutic armamentarium is relatively poor.
There is an acute necessity for trials with most drugs and
nutritional tools for complete validation. Promising seems
the role of ghrelin and melanocortin-receptor antagonists.
However, further studies are urgently needed to better
understand the pathogenic mechanisms of HD-related
anorexia and to see if amelioration of anorexia and
improvements in energy intake would result in a long-term
benefit in terms of increased quality of life and reduced
morbidity and mortality.
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